Rubius Therapeutics Inc (RUBY)
followers
·
Follow
| Sector: | HEALTH CARE |
| Industry: | BIOTECHNOLOGY & LIFE SCIENCES |
| SIC: | BIOLOGICAL PRODUCTS, (NO DISGNOSTIC SUBSTANCES) |
| CEO: | Dannielle Appelhans |
| Employees: | 6 |
| Web site: | rubiustx.com |
|
C/O VERDOLINO & LOWEY, P.C., 124 WASHINGTON STREET, SUITE 101, FOXBORO, MA, 02035
617-679-9600
| |
• *** This stock is shown as delisted in our database. *** If you think this isn't correct then please let us know
| All 13F Filers | Prior | Change | Hedge Funds 1 | Prior | Change |
|---|
Rubius Therapeutics, Inc. focuses on the development of red cell therapeutics (RCTs) for the treatment of patients with severe diseases. The company is developing RTX-240 and RTX-224 for the. treatment of solid tumors cancer. It is also developing. RTX-321 for the the treatment. of HPV-positive tumors;. and RTX-T1D for treating type 1 diabetes.
Please log in first to see chart